Get the Stockscreener App
3.205
3.39%
0.105
After Hours:
3.20
-0.005
-0.16%
Grace Therapeutics Inc stock is traded at $3.205, with a volume of 103.43K.
It is up +3.39% in the last 24 hours and down -6.97% over the past month.
Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage. Other products are GTx-102 Ataxia-Telangiectasia, GTx-101 Postherpetic Neuralgia, and GTx-201.
See More
Previous Close:
$3.10
Open:
$3.09
24h Volume:
103.43K
Relative Volume:
2.00
Market Cap:
$44.32M
Revenue:
-
Net Income/Loss:
$-11.61M
P/E Ratio:
-2.4757
EPS:
-1.2946
Net Cash Flow:
$-11.82M
1W Performance:
+8.09%
1M Performance:
-6.97%
6M Performance:
-7.77%
1Y Performance:
+0.00%
1-Day Range:
$3.09
$3.325
1-Week Range:
$2.85
$3.37
52-Week Range:
$1.75
$4.965
Grace Therapeutics Inc Stock (GRCE) Company Profile
Name
Grace Therapeutics Inc
Sector
Industry
Phone
609-322-1602
Address
103 CARNEGIE CENTER, PRINCETON
Compare GRCE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GRCE
Grace Therapeutics Inc
|
3.205 | 42.87M | 0 | -11.61M | -11.82M | -1.2946 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.77 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.93 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
637.56 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.10 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Grace Therapeutics Inc Stock (GRCE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-02-25 | Initiated | TD Cowen | Buy |
| Sep-01-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-06-20 | Upgrade | B. Riley FBR | Neutral → Buy |
| Jan-13-20 | Downgrade | B. Riley FBR | Buy → Neutral |
| Aug-29-19 | Initiated | B. Riley FBR | Buy |
| Jul-18-19 | Initiated | Oppenheimer | Outperform |
| Jun-26-19 | Initiated | H.C. Wainwright | Buy |
View All
Grace Therapeutics Inc Stock (GRCE) Latest News
Grace Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2025 - MarketScreener
Grace Therapeutics, Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Grace Therapeutics Announces First Quarter 2026 Financial Results, Provides Business Update - The Manila Times
Grace Therapeutics Q1 2026 Financial Results and Business Update - TradingView
Grace Therapeutics Seeks FDA Approval for First aSAH Treatment Innovation in 40 Years, Reports Q1 Results - Stock Titan
Grace Therapeutics Inc. stock chart pattern explainedSecure Asset Flow and Trend Pattern Analysis - Newser
Applying sector rotation models to Grace Therapeutics Inc.Triple Digit Gain Opportunity Watchlist - Newser
How to track smart money flows in Grace Therapeutics Inc.Strategy Builder for Growth Focused Traders - Newser
Is Grace Therapeutics Inc. meeting your algorithmic filter criteriaSmart Swing Picks with Confirmed Signals - Newser
Visual trend scoring systems applied to Grace Therapeutics Inc.Market Sentiment Tracker with Smart Alerts - Newser
Backtesting results for Grace Therapeutics Inc. trading strategiesWatchlist Generator for Smart Money Signals - Newser
Published on: 2025-08-10 22:04:39 - Newser
Candlestick signals on Grace Therapeutics Inc. stock todayBuy Strategy with Smart Exit Timing - Newser
How Grace Therapeutics Inc. stock performs during market volatilityGrowth Projection Summary for Long-Term Investors - Newser
Will Grace Therapeutics Inc. Stock Benefit from AI and Green Energy TrendsSmart Risk Entry Zone Technical Analysis - Newser
Statistical indicators supporting Grace Therapeutics Inc.’s strengthHigh Return Strategy with Low Risk - Newser
Why Grace Therapeutics Inc. stock attracts strong analyst attentionMulti-Bagger Detection with Trend Tools - Newser
Leading vs lagging indicators on Grace Therapeutics Inc. performance2-Day Signal Watch with Forecast Outcome - Newser
Reversal indicators forming on Grace Therapeutics Inc. stockTrade Alert System with Volume Analysis - Newser
Grace Therapeutics Inc.’s volatility index tracking explainedSecure Asset Flow and Trend Pattern Analysis - Newser
Using Bollinger Bands to evaluate Grace Therapeutics Inc.Buy and Exit Strategy Based on Momentum - Newser
Will Grace Therapeutics Inc. price bounce be sustainableWeekly Return Plan for Conservative Traders - Newser
Grace Therapeutics, Inc expected to post a loss of 22 cents a shareEarnings Preview - TradingView
Does Grace Therapeutics Inc. fit your quant trading modelPredictive System for Long-Term Stock Forecast - Newser
Sector Leaders Rotate Capital Into Grace Therapeutics Inc.High Win Rate Trading Opportunities Detected - metal.it
When is Grace Therapeutics Inc. stock expected to show significant growthAchieve rapid financial growth with smart picks - Jammu Links News
How strong is Grace Therapeutics Inc. company’s balance sheetCapitalize on market trends with confidence - Jammu Links News
What are Grace Therapeutics Inc. company’s key revenue driversFree Stock Market Beginners Guide - Jammu Links News
What institutional investors are buying Grace Therapeutics Inc. stockUnmatched profit potential - Jammu Links News
Why is Grace Therapeutics Inc. stock attracting strong analyst attentionPhenomenal trading returns - Jammu Links News
Is Grace Therapeutics Inc. stock overvalued or undervaluedBuild a winning investment strategy - Jammu Links News
What catalysts could drive Grace Therapeutics Inc. stock higher in 2025Achieve consistent profits with proven methods - Jammu Links News
What is Grace Therapeutics Inc. company’s growth strategyFree Wealth Planning Blueprint - Jammu Links News
How volatile is Grace Therapeutics Inc. stock compared to the marketAchieve superior returns with professional insights - Jammu Links News
Grace Therapeutics Inc Stock (GRCE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.91%
3.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):